German China

Germany: Accelerated Organic Growth

Eppendorf Increases 2018 Sales by 5.6 %

| Editor: Alexander Stark

Eppendorf increases sales and earnings in 2018 and accelerates organic growth.
Gallery: 1 image
Eppendorf increases sales and earnings in 2018 and accelerates organic growth. (Source: Eppendorf)

2018 was a very good fiscal year for the Eppendorf Group. The globally operating Hamburg-based life sciences company increased its Group sales by 5.6 % (organic growth in local currencies +8.2 %) to $ 822,57 million (previous year: $ 778,69 million).

Hamburg — Thomas Bachmann, President and Chief Executive Officer of Eppendorf is pleased that the company has once again grown faster than the market environment. The company developed positively in all markets and thus consistently continued its profitable growth course.

In North and South America, sales growth in local currencies amounted to 9.0 %, the average industry growth in the region was clearly exceeded. North America in particular contributed to Eppendorf outperforming the market. Europe also posted very good growth rates with sales growth of 5.7 % in local currencies. The strongest growth of 11.1 % in local currencies was recorded in the Asia/Pacific/Africa region. All countries in this region contributed to the very good business development, with growth rates in China and India being particularly noteworthy.

In 2018, numerous measures, projects and initiatives in the areas of market development, portfolio management, infrastructure and corporate culture were implemented as part of the realignment of the company. They set the course for the company's successful future and put the new global organization into effect. This is to enable the group to gear itself even better to the needs of the various markets and customers in the future. This also includes a comprehensive innovation initiative, within the framework of which numerous pilot projects for the product development have been carried out. In 2018, as in the previous year, Eppendorf significantly increased its expenditure on research and development. At $ 51,10 million (previous year: $ 41,17 million), these reached a new record level.

The company assumes that the positive economic mood in the industry and particularly in the USA will be maintained in 2019. Numerous product launches are planned for the first half of the year, which will contribute to the positive sales trend. As part of the targeted implementation of the corporate strategy, disproportionately high investments will continue to be made and the basis for further profitable and sustainable growth will be consolidated. Based on the planned higher costs, we estimate our Ebit will remain at the same level as the year before, given comparable exchange rates.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 45851264 / Laborpraxis Worldwide)